Jubilant Biosys Doubles Early Chemistry Scale-up Capacity with New Noida Facility in India

Noida, India, 12^th January, 2025: Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, and a global CRDMO operating from five sites across India and Europe, – announced the opening of a new discovery and preclinical facility at Noida [Delhi NCR], doubling its overall chemistry capacity for discovery research and scale-up projects.

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants, meeting growing demand in particular for fee-for-service (FFS) contracts.

“We have grown rapidly over the past year, well above the wider market, by expanding our FFS offerings, which enable innovators to advance discovery projects with lower risk. With improving funding conditions, we anticipate even higher demand next year, and this new facility doubles our existing capabilities. From a client perspective, we can now provide faster discovery delivery and integrated scale-up, with projects seamlessly transferred to our GMP facilities ready for any IND filing and commercial phases” commented Giuliano Perfetti, CEO - Jubilant Biosys Limited. 

The new Noida facility offers biotech and pharma partners a fully unified route from discovery to scale-up, augmenting the Company’s existing Chemistry Research Innovation Centre (CRIC) in Greater Noida [Delhi]. Collectively, this brings the total numbers of scientists across the business to more than 1300, with the new facility adding multiple manufacturing lines and having already onboarded several new clients.

Designed to handle quantities from hundreds of grams up to 25 kg, the new small-molecule hub combines two pilot plant blocks with co-located discovery labs. It features 20,000 sqft of state-of-the-art R&D space as well as 15 reactors spanning a variety of sizes from 20L through to 250L. Significantly, the facility has been designed with a potential to be expanded multifold in future and has room to quadruple capacity as client demand grows.

Jubilant Biosys Limited works with 8 of the top 20 pharma and earlier this year announced remarkable 42% rise in its first quarter revenue [FY26] from drug discovery projects,[1] predominantly driven by rising demand for FFS contracts.

Innovators will be provided comprehensive route scouting, process design and optimization, scalable synthesis development, analytical services including salt screening and polymorph evaluation and seamless technology transfer to pilot plants all from the specially designed campus.

-ENDS-

.

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with a global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in the manufacturing and supply of Radiopharmaceuticals with a network of 45 radiopharmacies in the US. The Company’s Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant Pharmova Limited through its CDMO Sterile Injectables business offers manufacturing services including sterile fill and finish injectables (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. The CRDMO business of the Company includes the Drug Discovery Services business that provides contract research and development services through two world-class research centers in Bengaluru and Noida in India and one in France. The CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in the Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a ‘Partner of Choice’ by leading pharmaceuticals companies globally.

For media enquiries, please contact:

Alex Heeley, Abdual Khalifeh or Nidhi Narain

De Facto Communications

T: +44 (0) 7834 785 764 /  +44 (0) 7463 317 575 /  +44 (0) 7769 015 043

E: a.heeley@defacto.co.uk  / a.khalifeh@defacto.co.uk / n.narain@defacto.co.uk 

[1] https://www.jubilantpharmova.com/Uploads/files/527pressfile_JubilantPharmovaLimitedFinancialResultsQ1FY26.pdf?utm_source=chatgpt.com